Oligonucleotide therapeutics at TIDES Europe 2026
Nov 3–5, 2026 Amsterdam, Netherlands ~900 attendees Website
69 organizations at TIDES Europe 2026 present work in oligonucleotides: 34 suppliers and service providers, 30 drug developers and 5 academic, government and non-profit bodies. Between them they bring 93 presentations to the program. Most represented: Novo Nordisk (6 on the program), Bachem (5 on the program), Roche (5 on the program). 40 of them have their own page in this guide. As of Sep 25, 2026.
Format
Top represented
Showing 1–9 of 69 organizations
| Organization | TIDES Europe 2026 Attendance |
|---|---|
Novo Nordisk Bagsværd, Denmark | |
Danish pharmaceutical company known for diabetes and obesity medicines, including the GLP-1 peptide drugs semaglutide and liraglutide. | Keynote Tue Nov 3 13:50–14:25 Next Generation GLP-1 Therapeutics How GLP-1 drugs for metabolic disease became longer-acting, and what it would take to dose them less often or swallow them as pills. PeptidesObesity & Metabolic Talk Wed Nov 4 08:05–08:35 Shifting Landscape: Global Regulatory CMC Guidance for Synthetic Oligonucleotides Where regulators around the world now agree and disagree on manufacturing and quality rules for synthetic oligonucleotides, and how those rules could align. Talk Thu Nov 5 09:05–09:35 Identity Testing of Synthetic Peptides: From Multi-Method Evaluation to a Compliant Two-Test Scheme Why two well-chosen laboratory tests can prove a manufactured peptide is the intended molecule, rather than the longer list of tests regulators expect. Talk Thu Nov 5 08:35–09:05 siRNA Conjugate Mediated Delivery to Disease Specific Cell Types Occurs through a Novel Mechanism How siRNA drugs attached to a carrier reach the cells behind chronic inflammatory disease and cancer, and how that route was worked out. Talk Fri Nov 6 09:10–10:00 Keynote Panel: From Lab to Launch - Navigating the European Obesity Therapeutics Landscape What it takes to turn obesity research into a product Europe will approve, manufacture at scale and actually pay for. Talk Fri Nov 6 08:40–09:10 Keynote Presentation: Decoding The Future of Obesity Care: The Signals Worth Paying Attention To Where obesity drug development stands in 2026 and which companies and market openings across Europe are worth watching. Talk Fri Nov 6 12:00–12:25 |
Bachem Bubendorf, Switzerland | |
Contract development and manufacturing organization for peptide and oligonucleotide active pharmaceutical ingredients, from research quantities to commercial scale. | Booth Exhibiting (no floor booth listed) Wed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm Talk Wed Nov 4 15:00–15:30 A Mild and Sustainable Platform for Disulfide Bond Formation in Peptide Manufacturing Using Dehydroascorbic Acid Using an oxidised form of vitamin C instead of harsh chemicals to form the sulfur bridges that hold many peptide drugs in shape. Talk Wed Nov 4 14:30–15:00 Beyond Packed Beds: Advancing Scalable Oligonucleotide Manufacturing Through Stirred-Bed Technology Building oligonucleotides in a continuously stirred reactor rather than a packed column, so reagents mix evenly and batches can reach ton scale. Talk Wed Nov 4 16:15–16:45 Dapiglutide: From Lab to Large Scale Manufacture through Innovative Peptide Process Development How process changes in making the peptide drug dapiglutide raised its overall yield from about 20% to over 60%. Talk Wed Nov 4 11:50–12:20 Digital Manufacturing in Practice: Enabling Efficient and Compliant Large-scale Production Running large-scale production on digital records and automation, and what that changed for output, consistency and the ability to spot process problems. CMC & Manufacturing Talk Thu Nov 5 08:00–08:05 |
Roche Basel, Switzerland | |
Swiss pharmaceutical and diagnostics company with oligonucleotide and peptide programmes in its drug pipeline. | Chair Wed Nov 4 08:00–08:05 Talk Wed Nov 4 14:00–14:30 Enzymatic Ligation for the Production of Oligonucleotides Screening many ways to cut and rejoin siRNA strands with enzymes, then scaling the best one up for cleaner, higher-yield production. Talk Wed Nov 4 08:05–08:35 Shifting Landscape: Global Regulatory CMC Guidance for Synthetic Oligonucleotides Where regulators around the world now agree and disagree on manufacturing and quality rules for synthetic oligonucleotides, and how those rules could align. Talk Thu Nov 5 10:45–11:15 MCSGP Process Control and Characterization Strategy Keeping a multi-column peptide purification system dependable by working out which settings must stay within range to hold purity steady at full scale. Talk Thu Nov 5 11:15–11:45 Regulatory Insights from Recent Global Phase 3 Peptide Filings What health authorities asked about manufacturing, quality control and delivery devices during recent late-stage applications for peptide drugs. |
AstraZeneca Cambridge, United Kingdom | |
Global pharmaceutical company developing medicines across modalities, including oligonucleotide and peptide therapeutics. | Talk Thu Nov 5 15:00–15:30 Maintaining Diastereomeric Control in Phosphorothioate siRNAs: Integrated Analytical and Manufacturing Approaches for Reliable Clinical Development Why purifying siRNA can quietly shift the mix of mirror-image sulfur linkages between batches, and how to keep that mix steady. Talk Thu Nov 5 09:05–09:35 Peptide-Targeted Delivery of Oligonucleotide Therapeutics Early, pre-clinical work on a short peptide that steers gene-silencing drugs into the tissue where they are meant to act. Talk Thu Nov 5 09:05–09:35 Rethinking Green Credentials for Oligo Manufacturing Why simple waste-per-kilogram scores misjudge how green oligonucleotide production is, and what real improvement would involve. Talk Thu Nov 5 08:35–09:05 Systematic Route Design for Fragment-Based Peptide Synthesis: Enabling Liquid-Phase Transition A way to choose where to split a long peptide into fragments so it can be built in solution with better yield. |
Eli Lilly and Company Indianapolis, IN | |
Global pharmaceutical company whose peptide medicines include tirzepatide, with programs in oligonucleotide therapeutics. | Keynote Tue Nov 3 13:15–13:50 Making Oligonucleotides a High-Volume Reality: Next-Gen Platforms and Strategy for Oligonucleotide Manufacturing OligonucleotidesCMC & Manufacturing Keynote Tue Nov 3 14:25–15:00 Retatrutide: From Breakthrough Science to Global Medicine — The CMC Story Behind a Novel GIP, GLP-1, and Glucagon Receptor Agonist How the obesity and diabetes drug retatrutide is made at world supply scale by joining peptide fragments in solution with far less waste. PeptidesCMC & Manufacturing Talk Wed Nov 4 16:45–17:15 Made to Scale: What Tirzepatide's Manufacturing Challenge Teaches Us About Innovation Under Pressure Lessons from scaling up production of the diabetes and obesity drug tirzepatide, from an odd result at the bench to tonnes of material. Talk Thu Nov 5 16:00–16:30 Cycle Time Is a Quality Metric: Eloralintide from Discovery to Clinical Proof of Concept How the peptide eloralintide moved from discovery into patients by overlapping chemistry and biology cycles instead of running them one after another. |
Agilent Technologies Santa Clara, CA | |
Makes liquid chromatography, mass spectrometry and other analytical instruments, and manufactures oligonucleotide active pharmaceutical ingredients under contract. | Booth Exhibiting at Booth 317 Wed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm Talk Wed Nov 4 16:45–17:15 Analytical Method Validation Across the Oligonucleotide Lifecycle How a contract manufacturer validates the tests used to check oligonucleotide drugs, from raw materials to release, without slowing development. Talk Wed Nov 4 11:50–12:20 Integrated Analytical Workflows for Synthetic Peptide Development: From Peptide Separation to Sequence Confirmation Combining separation, mass measurement and software to confirm a synthetic peptide's sequence, purity and starting materials at every stage. PeptidesCMC & Manufacturing |
Almac Craigavon, United Kingdom | |
Drug development services for small molecules and peptides, including analytical testing, API supply, radiolabelling, formulation and solid-state services. | Booth Exhibiting at Booth 227 Wed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm Talk Tue Nov 3 11:00–11:30 Individualised Cancer Vaccines: Developing a High-throughput cGMP Peptide Manufacturing Philosophy How to make twenty different peptides to clinical quality in twenty days for one patient's personalised cancer vaccine, then do it again. Talk Thu Nov 5 10:45–11:25 Part 1: siRELIS: A Convergent Enzymatic Ligation Strategy for siRNA Manufacturing; Part 2: Enzyme Development for Oligonucleotide Therapeutics Manufacturing Using engineered joining enzymes to assemble siRNA from short building blocks, and what scaling that approach taught two companies. |
Asymchem Tianjin, China | |
Contract development and manufacturing organization for small molecules, oligonucleotides and peptides, with flow chemistry and enzymatic process capabilities. | Booth Exhibiting (no floor booth listed) Wed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm Talk Tue Nov 3 12:15–12:45 Innovating Oligonucleotide Production: Enzymatic Fragment Ligation for siRNA Joining short RNA fragments with enzymes in water instead of standard solid-phase steps, for purer siRNA at lower cost and larger scale. OligonucleotidesCMC & Manufacturing Talk Thu Nov 5 07:30–08:00 Advancing TIDES with Flow Chemistry How running peptide and oligonucleotide chemistry as a continuous flowing stream tightens control, improves safety and cuts waste. CMC & Manufacturing |
Axolabs Kulmbach, Germany | |
Oligonucleotide contract research and manufacturing organization offering discovery, preclinical, analytical and GMP manufacturing services. | Booth Exhibiting (no floor booth listed) Wed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm Talk Tue Nov 3 09:00–12:00 CMC Decisions That Influence Cost of Goods (COGs) in Oligo Scale-up: Levers for Scientific and Commercial Impact Which early manufacturing and quality decisions set what an oligonucleotide drug costs to produce, and when in development they should be taken. Talk Wed Nov 4 13:25–13:55 From Development Candidate Nomination to First-in-Human: Accelerating Oligonucleotide Development Through Integrated Strategies What it took to move a sugar-tagged siRNA candidate from selection to its first human trial on a tight schedule. OligonucleotidesCMC & Manufacturing |
Instantly find 20 buyers in oligonucleotides
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse TIDES Europe 2026 by
Organization type
Focus
Exhibit hall
Everyone
Not affiliated with or endorsed by Informa Connect or TIDES Europe. Submit a correction